VJHemOnc Podcast

In this insightful discussion, Dr. Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center shares his expertise on treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). He dives into the challenges of managing this rare cancer and reviews current therapies like tagraxofusp. The conversation also covers patient eligibility, the role of stem cell transplants, and emerging treatments targeting CD123. Dr. Pemmaraju highlights ongoing clinical trials that promise to advance treatment strategies and improve outcomes for BPDCN patients.

Discover innovative strategies for pain management in patients with sickle cell disease and the transformative Universal Care Plan initiative. Learn about the Sickle Eye Project, which aims to tackle visual impairments linked to the condition. Uncover the critical healthcare gaps in sub-Saharan Africa, such as the need for newborn screening. The podcast also emphasizes the psychosocial needs of patients, advocating for integrated mental health services to support their emotional well-being.

Expert guests Marlise Luskin, a hematology specialist, Nicole LeBoeuf, a dermatologist, and hematologist Shai Shimony from Dana-Farber Cancer Institute discuss blastic plasmacytoid dendritic cell neoplasm (BPDCN). They delve into its unique symptoms, including deep purple skin lesions, diagnostic challenges, and the necessity of a multidisciplinary approach. The conversation also highlights treatment options like tagraxofusp and venetoclax, advancements in targeted therapies, and the critical role of collaboration among healthcare professionals to improve outcomes for patients.

Dr. Monique Minnema from University Medical Center Utrecht, a specialist in Bing-Neel syndrome, joins the discussion on managing complications of Waldenström’s macroglobulinemia. Key topics include the challenges in diagnosing Bing-Neel syndrome and the potential of treatments like rituximab and ibrutinib. The conversation also touches on the link between acquired von Willebrand disease and WM, emphasizing the risks of bleeding complications, and highlights the importance of monitoring and new strategies for patient care.

Krina Patel, an expert in CAR T-cell therapies at MD Anderson Cancer Center, dives into the cutting-edge treatments for high-risk multiple myeloma. She discusses the latest clinical trial findings and how CAR-T therapies are tailored for specific high-risk subgroups. The conversation also touches on the potential of allogeneic CAR T-cell products. Additionally, there’s a focus on bispecific antibodies, with insights on resistance mechanisms and combination strategies that may enhance treatment efficacy. This is an enlightening listen for cancer care innovators!

Marina Konopleva is the Director of Leukemia at Montefiore Cancer Center, while Emma Groarke is an Associate Research Physician at the NIH. They delve into the landscape of rare myeloid diseases like BPDCN, CMML, and VEXAS, discussing innovative therapies including Tagrexofaspa and IDH inhibitors. The conversation highlights the complexities in treatment due to patient variability and the significance of risk stratification in decision-making. They also emphasize the importance of collaborative research to enhance outcomes in these challenging conditions.

Join experts Krish Patel, MD, specializing in mantle cell lymphoma treatment, Marek Trněný, MD, PhD, a key contributor to BTK inhibitor trials, and Michael Wang, MD, who offers insights on therapeutic sequencing. They delve into groundbreaking trials like ECHO and SHINE, discussing the role of BTK inhibitors and their effectiveness for older patients. Notably, they address optimal sequencing methods to prevent cross-resistance and strategies for managing cardiac toxicities. Their collaboration underscores a comprehensive approach to enhancing patient care.

Join experts Joshua Zeidner, MD from UNC Lineberger and Eunice Wang, MD from Roswell Park as they dive into the latest breakthroughs in menin inhibitors for acute myeloid leukemia (AML). They unravel how these inhibitors work against specific genetic mutations, offering hope in treating AML. The conversation covers exciting new data presented at the iwAL 2024, challenges in developing resistance, and the innovative combinations being explored to enhance efficacy. Get ready to learn about the future of targeted treatments in AML!

In this discussion, Stephen Schuster and Jason Westin from top cancer centers delve into the latest in CAR T-cell therapy for non-Hodgkin lymphoma. They explore the treatment landscape, strategies to manage toxicities, and the promise of allogeneic CAR-T products. Joining them, Stephen Ansell and Martin Hutchings share insights on the role of bispecific antibodies, comparing their efficacy against CAR T therapies. They also address unique challenges and exciting combinations with antibody-drug conjugates that could redefine treatment approaches.

In this engaging discussion, Harry Erba, a professor at Duke University, shares insights on prolonging remission in acute myeloid leukemia (AML). Joined by Farhad Ravandi from MD Anderson, they delve into the significance of measurable residual disease (MRD) assays in customizing post-remission therapies. Thomas Cluzeau from Central University Hospital of Nice emphasizes the role of allogeneic stem cell transplantation and innovative maintenance therapies. The trio explores new treatments like CPX351 and the essential nature of ongoing clinical trials to improve patient survival.